CLAIMS

What is claimed is:

A selective growth medium specific for *Listeria spp*. comprising, in combination,
lithium chloride and one or more antibiotics or salts thereof, in concentrations effective to selectively inhibit non-*Listeria* organisms while enhancing growth of *Listeria spp*.

- 2. The medium of claim 1, wherein the antibiotics are selected from the group consisting of ceftazimide, phosphomycin, polymyxin, and nitrofurantoin.
 - 3. The medium of claim 1, being substantially devoid of acriflavin.
 - 4. The medium of claim 1, further comprising esculin.

15

- 5. The medium of claim 1, wherein the lithium chloride is present in a concentration of from about 1 g/L to about 10 g/L.
- 6. The medium of claim 5, wherein the lithium chloride is present in a concentration of from about 5 g/L.
 - 7. The medium of claim 2, wherein the nitrofurantoin is present in a concentration of from about .001 g/L to about 0.01g/L.
- 25 8. The medium of claim 7, wherein the nitrofurantoin is present in a concentration of about .006 g/L.

. 1 . . 1 .

9. A selective and differential medium for *Listeria spp*. comprising an agar base layer substantially devoid of, acriflavin, the base layer containing lithium chloride, a growth enhancer of *Listeria spp*., and antibiotics or salts thereof in concentrations effective to selectively inhibit non-*Listeria* organisms.

5

- 10. The medium of claim 9, wherein the growth enhancer comprises an iron-containing compound.
- 11. The medium of claim 10, wherein the growth enhancer is ferric ammonium citrate.

10

- 12. The medium of claim 9, wherein the antibiotics are selected from the group consisting of ceftazimide, phosphomycin, polymyxin, and nitrofurantoin.
- 13. The medium of claim 12, wherein the polymyxin is polymyxin E.

15

14. A *Listeria spp*.-selective medium comprising, in combination, tryptone, peptone, sodium chloride, dibasic potassium phosphate, yeast extract, cyclohexamide, naladixic acid, ferric ammonium citrate, and esculin, in concentrations effective to promote growth of *Listeria spp*.

20

- 15. The medium of claim 14, further comprising, in combination, ceftazimide, phosphomycin, polymyxin E, lithium chloride, and nitrofurantoin in concentrations effective to inhibit growth of non-*Listeria* organisms.
- 25 16. The medium of claim 14, the medium being substantially devoid of acriflavin.
 - 17. The medium of claim 14, wherein the tryptone concentration is about 17.0 g/L.
 - 18. The medium of claim 14, wherein the peptone concentration is about 3.0 g/L.

5-1

30

19. The medium of claim 14, wherein the sodium chloride concentration is about 5.0 g/L.

- 20. The medium of claim 14, wherein the dibasic potassium phosphate concentration is about 6.0 g/L.
 - 21. The medium of claim 14, wherein the yeast extract concentration is about 6.0 g/L.
- 22. The medium of claim 14, wherein the cyclohexamide concentration is about 0.05 g/L.

. .

- 23. The medium of claim 14, wherein the naladixic acid concentration is about 0.04 g/L.
- 15 24. The medium of claim 14, wherein the esculin concentration is about 1.0 g/L.
 - 25. The medium of claim 15, wherein the ceftazimide concentration is about 0.04 g/L.
- 26. The medium of claim 15, wherein the phosphomycin concentration is about 0.04 g/L.
 - 27. The medium of claim 15, wherein the polymyxin E concentration is about 0.01 g/L.
- 28. The medium of claim 14, wherein the ferric ammonium citrate concentration is about 0.5 g/L.
 - 29. The medium of claim 15, wherein the lithium chloride concentration is about 5.0 g/L.

30. The medium of claim 15, wherein the nitrofurantoin concentration is about .006 g/L.

- 5 31. A Listeria spp.-selective medium comprising, in combination,
 - a. tryptone, in a concentration of about 17.0 g/L;
 - b. peptone, in a concentration of about 3.0 g/L;
 - c. sodium chloride, in a concentration of about 5.0 g/L,
 - d. anhydrous dibasic potassium phosphate, in a concentration of about 6.0 g/L;
- e. yeast extract, in a concentration of about 6.0 g/L;
 - f. cyclohexamide, in a concentration of about 0.05 g/L;
 - g. naladixic acid, in a concentration of about 0.04 g/L;
 - h. esculin, in a concentration of about 1.0 g/L;
 - i. ceftazimide, in a concentration of about 0.04 g/L;
- j. phosphomycin, in a concentration of about 0.04 g/L;
 - k. polymyxin E, in a concentration of about 0.01 g/L;
 - 1. ferric ammonium citrate, in a concentration of about 0.5 g/L;
 - m. lithium chloride, in a concentration of about 5.0 g/L; and
 - n. nitrofurantoin, in a concentration of about 0.006 g/L.